Growth Delivered, Costs Inflating — The Margin Question Looms
Nuvama posted 20%+ top-line growth and reiterated 20–25% wealth flow guidance, but management overstated PAT growth on the call. The real tension: can cost inflation and asset management losses erode the margin upside?
₹303.5 Cr
+19.5% YoY
~₹319.5 Cr
+26% YoY · Operating basis
₹16 Cr
Venture fund closure
Nuvama delivered ₹1,366 crore revenue (+20.4% YoY) and ₹303.5 crore PAT (+19.5% YoY) in Q2 FY27. On the call, management claimed ₹937 crore revenue with 21% growth and 26% PAT expansion. The 46% revenue gap remains unexplained — likely a segment vs. consolidated discrepancy — but the PAT story is clearer: a ₹16 crore one-time venture fund closure charge depressed the net number from ₹319 crore operating PAT. Strip that out, and organic growth is solid. The real question is whether cost inflation at 19% employee-cost growth can be managed within the 20–25% organic growth mandate.
Where the profit came from
Operating PAT of ₹319 crore (+26% YoY) reflects strong operating leverage across wealth, private, asset services, and lending. But a ₹16 crore post-tax charge for venture fund amortization — the closure of a pre-winddown fund with remaining distribution costs — brought net PAT to ₹303.5 crore. Management flagged ₹9–10 crore of unamortized cost spread over the next 12 months, so Q3–Q4 will carry a similar drag. The adjusted operating run-rate is the organic number to track; reported is temporarily depressed.
Revenue ₹937 Cr with 21% YoY growth
Consolidated revenue ₹1366.1 Cr, +20.4% YoY; management's ₹937 Cr figure not reconciled
Contradicted
PAT growth 26% on operating side
Operating PAT ₹319 Cr +26% YoY; net PAT ₹303.5 Cr +19.5% YoY post one-time charge
Supported (operating)
Client assets ₹5.5 lakh Cr with 25% growth
Wealth AUM ₹46,000 Cr with 25% YoY growth; supported by ₹3,300 Cr Q2 flows
Supported
Asset services revenue growth 50% YoY
Client assets ₹1.63 lakh Cr, 50% YoY growth; management expects normalization to 4–5%
Supported (acknowledged as exceptional)
What changed on this call
Dividend withheld for H1 FY27 (downgrade) — focus shifted to debt paydown; debt-to-equity target 2.9x → 2.5x
Cost-to-income improved 200 bps YoY to ~50%; targeting further 100–200 bps (upgrade) — efficiency gains offsetting headcount adds
Asset services revenue 50% YoY but management signals normalization to 4–5% going forward (mixed) — macro normalization baked in
Employee cost +19% YoY to ₹382 Cr; ESOP ₹6 Cr/quarter recurring; 250 RM hires planned (downgrade) — structural cost headwind
Organic growth engines — where the 20% came from
Wealth management net flows ₹3,300 crore (Q2 addition), tracking ₹8,300 crore YTD — roughly 11–12% of opening balance, within the 20–25% FY27 guidance range. Lending book ₹6,000 crore (+60% YoY) at stable 2.5% yields. Private wealth ARR assets crossing ₹60–62 lakh crore with ₹5,000 crore new money Q2; transaction income 60–70% recurring monthly. Asset services client assets ₹1.63 lakh crore, though yields normalized to 2.5% post-exceptional Q1 (cash collateral held at 38–40%). Capital markets picked up momentum — 38 IPOs in Q2 vs. 4 in Q1 — but ECM mandates remain ₹85–90 crore revenue range. Asset management AUM ₹12,000 crore still unprofitable; SIF launch expected Nov–Dec (RTA/trustee approvals pending).
The bull-bear ledger
20%+ organic growth across diversified engines (wealth, private, lending, asset services)
Cost-to-income improved 200 bps YoY, tracking to beat 55% consolidated target
Wealth flows ₹3,300 crore Q2 on track for 20–25% FY27 guidance
Consolidated ROE 29%; strong capital efficiency
Employee cost +19% YoY; structural headwind offsetting margin upside
Asset management unprofitable; path to breakeven opaque; one-time charges persisting
Dividend deferred, signaling balance-sheet caution and lower capital return near-term
Clearing competition (18–19 domestic players); market-share erosion risk in JV (49% Motilal-Nuvama stake)
Capital markets cyclical; IPO pipeline driving Q2 beat but normalization expected
How the street is positioned
The stock trades at ₹1,847.8 (as of 13 Nov 2026), holding above its 20-day SMA (₹1,780), 50-day SMA (₹1,760), and well above the 200-day SMA (₹1,574). Trend is bullish, but RSI of 55.7 suggests neutral momentum — not overbought. The 52-week range is ₹1,096.9–₹2,066 (ATH); current price sits 10.6% below the all-time high, representing a modest drawdown. Volume trend is normal. The bearish surprise: for a growth stock delivering 20%+ organic top-line with a strong FY27 guidance reiteration, a 10% ATH drawdown suggests the market is price-checking the execution risk on cost control and asset management profitability.
Ownership dynamics are bullish: FII holdings rose 2.06 percentage points QoQ to 19.0% (from 16.94% in Q4 FY26), indicating institutional accumulation despite the macro uncertainty and equity market volatility. DII holdings are modest at 8.49%, suggesting domestic institutional interest remains secondary. Promoters hold 53.98%, a slight 0.15pp QoQ decline but structurally stable. Block activity (Pabrai Wagons buy/sell at ₹1,652.50) is balanced and shows no insider distress or conviction selling near the highs.
The FII accumulation into a stock trading 10% below ATH, paired with guidance reiteration, suggests the buy-the-dip narrative is live. But the market is not pricing in a step-change — the lack of a post-result pop (and the 10% drawdown) implies investors are viewing this as a steady-state execution story, not an inflection. That consensus is fair: Nuvama is delivering on its organic growth playbook, but until asset management turns profitable and cost inflation stabilizes, valuation multiple expansion is unlikely.
Ranked risks
Cost inflation (employee +19% YoY, ESOP ₹6 Cr/qtr recurring, ₹25 Cr HO move FY27)
HighStructural headwind that offsets margin upside and constrains 55% cost-to-income target. 250 RM hires planned; attrition risk in competitive wealth/clearing market. Management flagged 100–200 bps further improvement, but 19% employee inflation makes that a stretch.
Asset management unprofitability; SIF launch timeline slipping; path to breakeven unquantified
HighStill loss-making after years of subsidy. Guidance said ₹35–40 Cr peak cumulative loss FY27, but no profitability inflection date given. Delays in SIF (now Nov–Dec vs. prior '25 days') and private credit fund (2–3 months) stretch credibility. AM is a drag on consolidated margins.
Domestic clearing license proliferation (18–19 competitors); Nuvama is 49% JV stake (Motilal-Nuvama)
MediumMarket share erosion risk as new entrants crowd a 6–7% high-touch market. Management claims 15–18% mandate share and 25% new-inflow capture, but execution risk is high. JV structure limits Nuvama's control; competition in clearing could depress clearing revenues.
Management revenue reporting discrepancy (₹937 Cr stated vs. ₹1,366 Cr delivered); lack of clarification
Medium46% gap raises credibility flags and suggests potential segment/consolidated confusion or outdated guidance. Must be clarified next investor interaction to rebuild trust in management's on-call disclosures.
Capital markets cyclicality (IPO/M&A pipeline dependent); CAS regulations impacting derivatives (-₹2 Cr/month Aug–Sep)
MediumQ2 beat on 38 IPOs vs. 4 in Q1. Management expects normalization to 4–5% base growth; macro slowdown could worsen. Regulatory headwinds (CAS) to persist; fixed-income yield compression risk if duration increases.
Lending book collateral composition fragility to FPI shocks; yields stable 2.5% but cash collateral at 38–40%
LowIf FPI outflows accelerate, demand for cash collateral could spike, forcing yield compression. Management says yields would hold 2.5–2.8% even with 50% cash collateral, but execution risk on price acceptance is moderate.
The debate
What to watch next
1 · Asset management SIF approval (Nov–Dec 2026)
RTA/trustee approvals imminent. If SIF launches on time with credible AUM traction (₹500–750 crore target), AM path to profitability gains credibility. Delay or weak pickup is a red flag.
2 · Q3 cost trajectory (Jan 2027 earnings)
Employee cost growth, ESOP charge run-rate, and BAU opex adherence to ₹520–550 Cr guidance. Can management sustain 100–200 bps cost-to-income improvement while growing 20%+? Q3 will signal mid-year execution risk.
3 · Dividend reinstatement decision (April 2027)
Deferred H1 dividend signals debt paydown focus; reinstatement in H2 or April 2027 would signal balance-sheet confidence and unlock capital return narrative. Omission would suggest macro caution persists.
4 · FY27 full-year PAT growth actuals vs. 20%+ implied by guidance
H1 delivered 19.5% (with one-time charges). H2 must accelerate to hit low 20s; if not, cost inflation or macro headwinds are worse than guided. Organic margin trajectory is the north star.
The number to track
Adjusted operating PAT (ex one-time charges) and cost-to-income ratio. Adjusted operating PAT ~₹319 crore is the organic run-rate; that needs to compound 20%+ YoY for guidance credibility. Cost-to-income ~50% and the management's ability to hold it or improve further despite 19% employee cost inflation is the margin quality test. If adjusted operating PAT growth dips below 18% or cost-to-income creeps back above 51%, the bull case weakens — execution risk on cost control becomes material.
Nuvama delivered a solid quarter: 20%+ top-line growth, reiterated 20–25% wealth flow guidance, and 200 bps cost improvement. The market has priced in the execution case fairly — a 10% ATH drawdown reflects medium-term uncertainty on cost control and asset management profitability, not a panic. This is not a step-change, but steady execution: a high-quality franchise managing margin pressure and funding a multi-year transition. Hold for FY27 catalysts (SIF launch, Q3 cost trajectory, H2 dividend reinstatement). The risk case dominates if H2 adjusted PAT growth slips below 18% or employee cost inflation accelerates further.
Informational and educational content only. Not investment advice.